You are here

povorcitinib

Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive'

Investors Business Daily

Mon, 03/17/25 - 10:14 pm

clinical trials

hidradenitis suppurativa

Incyte posts phase 3 skin condition wins but details disappoint, sinking stock

Fierce Biotech

Mon, 03/17/25 - 11:05 am

clinical trials

Incyte, itching for a piece of Dupixent's market, hits goals in midphase skin disease trial

Fierce Biotech

Mon, 03/11/24 - 11:52 am

clinical trials

prurigo nodularis

Incyte touts mid-stage data for new JAK inhibitor but stops short of selecting PhIII dose

Endpoints

Tue, 03/21/23 - 10:06 am

Incyte reports data from Phase IIb vitiligo therapy trial

Clinical Trials Arena

Mon, 03/20/23 - 11:27 am

clinical trials

Incyte reports new data from hidradenitis suppurativa therapy trial

Clinical Trials Arena

Mon, 02/13/23 - 10:25 am

clinical trials

hidradenitis suppurativa